Compare Hafnia Limited Common Shares (HAFN) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs Medline Inc. Class A Common Stock — how do they compare? Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B), while Medline Inc. Class A Common Stock trades at $36 (market cap $31.54B). The key difference: Medline Inc. Class A Common Stock is far larger — about 5.6× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays a 10.44% dividend while Medline Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Medline Inc. Class A Common Stock for 6 Days on average.
| HAFN | MDLN | |
|---|---|---|
Market Cap | $5.67B | $31.54B |
Volume | 3,240,007 | 4,637,232 |
Sector | Industrials | Health |
52-Week High | $10.92 | $49.99 |
52-Week Low | $5.21 | $31.64 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.29B | $41.50B |
Dividend Yield | 10.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
